

44-4-200
LS-2

2740-483 8

Pharmacological Aspects of Drug Dependence

Toward an Integrated Neurobehavioral Approach

Contributors

R.L. Balster, P.B.S. Clarke, D.R. Compton, L.A. Dykstra
G.I. Elmer, M.W. Fischman, R.A. Glennon, D.J. Greenblatt
R.R. Griffiths, L.S. Harris, K. Hellevuo, J.E. Henningfield
P.L. Hoffman, J.R. Hughes, C.-E. Johanson, R.M. Keenan
H.D. Kleber, T.R. Kosten, M.J. Kreek, M.J. Kuhar
M.C. LaBuda, F.R. Levin, A.H. Lichtman, B.R. Martin
L.G. Miller, G.K. Mumford, R.W. Pickens, C.R. Schuster
B. Tabakoff, G.R. Uhl, F.J. Vocci, E.A. Wallace, J. Willetts

Editors

Charles R. Schuster and Michael J. Kuhar



Springer

2F.

Contents

I. Research in the Study of Drug Action and Addiction

CHAPTER 1

Genetic Vulnerability to Substance Abuse

R.W. PICKENS, G.I. ELMER, M.C. LABUDA, and G.R. UHL

With 1 Figure	3
A. Heterogeneity of Drug Abuse	3
I. Etiological Influences	5
1. Risk Factors	5
2. Genetic Influences	6
B. Clinical Studies	8
I. Family Genetic Studies	9
1. Alcoholism	9
2. Other Drug Abuse	12
II. Levels of Genetic Analysis	14
1. Factors Affecting Use	15
2. Metabolism	15
3. Subjective and Objective Effects	16
4. Drug Specificity	16
5. Alternative Modes of Transmission	17
6. Phenocopies	18
C. Molecular Studies	18
I. Selecting Genetic Markers	19
II. Linkage Analysis	20
1. Dopamine D ₂ Receptor Locus	20
2. Other Genes	23
D. Animal Studies	23
I. Animal Models of Drug Taking Behavior	24
1. Behavioral Pharmacology Approach	24
2. Behavioral Genetics Approach	26
II. Genetic Variation in Drug Self-Administration and Drug-Reinforced Behavior	27
1. Two-Bottle Choice	27
2. Conditioned Place Preference	29

3. Intracranial Self-Stimulation	29
4. Operant Self-Administration	30
III. Drug-Naive Behaviors as Predictors of Vulnerability	32
IV. Neurobiological Markers as Predictors of Vulnerability	34
V. Response to Abused Drugs as Predictors of Vulnerability ..	36
E. Summary	38
References	39

CHAPTER 2

Integrative Neurobehavioral Pharmacology: Focus on Cocaine

M.J. KUHAH and C.R. SCHUSTER. With 8 Figures	53
A. Introduction	53
B. Approaches to Drug Abuse and Dependence	54
C. A Cocaine Receptor	55
I. Behavioral Models for Drug Abuse	56
1. Drug Self-Administration	56
2. Place Preference	58
3. Alteration of Thresholds for Electrical Brain Stimulation Reinforcement	58
4. Drugs of Abuse and Endogenous Reward Systems	59
II. Receptor Binding	60
III. Interdisciplinary Support for a Dopamine Hypothesis	63
D. Brain Imaging	66
E. Molecular Actions of Cocaine	71
I. Cloning the Dopamine Transporter/Cocaine Receptor	71
II. Effects of Chronic Cocaine Administration and Withdrawal	74
F. Conclusions	74
References	75

II. Molecular, Behavioral, and Human Pharmacology of Dependence and Consequences

CHAPTER 3

Marihuana

D.R. COMPTON, L.S. HARRIS, A.H. LICHTMAN, and B.R. MARTIN With 2 Figures	83
A. Introduction	83
B. Cellular and Molecular Effects	85
I. Neurochemistry	85

1. Effects on Neurotransmitters	85
2. Receptors	90
3. Second Messenger and Other Transduction Mechanisms	97
4. Integration of Systems	103
C. General Pharmacology	107
I. Pharmacokinetics	107
1. Absorption and Distribution	107
2. Metabolism and Excretion	108
3. Relationship of THC Levels to Effects	109
II. Effects on Organ Systems	110
1. Brain	110
2. Immune System	111
3. Endocrine	114
4. Cardiovascular	118
5. Gastrointestinal	119
6. Renal	119
III. Toxicity	119
1. Respiratory Effects	119
2. Psychotic Episodes	120
3. Neurochemical and Histological Effects	121
IV. Tolerance	122
1. Animals	122
2. Humans	123
V. Dependence	123
1. Animals	123
2. Humans	125
VI. Δ^9 -THC During Pregnancy	127
1. Effect on Dams and Litters	127
2. Developmental Toxicity	127
3. Neural Development	128
4. Teratogenicity	128
5. Fetotoxicity – Interactions with Ethanol	129
D. Behavioral Pharmacology	129
I. Unlearned Behaviors/Ethology	129
1. General Comments	129
2. Consummatory Behavior	130
3. Motor Behavior	130
4. Social Behavior	132
II. Conditioned Effects	133
1. Drug Discrimination	133
2. Self-Administration	134
3. Performance, Memory and Learning	135
E. Conclusions	138
References	138

CHAPTER 4

Cocaine

M.W. FISCHMAN and C.-E. JOHANSON	159
A. History and Epidemiology	159
B. General Pharmacology	161
I. Pharmacokinetics	161
II. Organ and System Toxicity	163
III. Fetal and Developmental Toxicity	165
IV. Behavioral Toxicity	167
C. Neurobiology of Cocaine's Behavioral Effects	167
I. Receptor Targets	168
II. Sensitization	169
III. Reinforcement	174
IV. Medications Development	178
D. Final Comments	182
References	182

CHAPTER 5

Opioid Analgesics

L. DYKSTRA. With 4 Figures	197
A. Background	197
B. Cellular and Molecular Effects	200
I. Opioid Receptors	200
1. Early Discoveries	200
2. Opioid Receptor Multiplicity	200
3. Selective Opioid Agonists and Antagonists	202
4. Distribution	204
II. Postreceptor Events	204
C. General Pharmacology	205
I. Pharmacokinetics and Metabolism	205
II. General Effects	205
III. Immune Function	206
IV. Analgesia	207
1. Clinical Observations	207
2. Mechanism of Action of Mu Agonists	207
3. Kappa and Delta Agonists	208
V. Tolerance	209
VI. Physical Dependence	210
D. Behavioral Pharmacology	211
I. Reinforcing Effects	211
1. Self-Administration and Place Preference	211
2. Neurobiological Mechanisms	214

II. Discriminative Stimulus Characteristics	215
III. Schedule-Controlled Behavior	217
IV. Conditioned Drug Effects	219
V. Learning and Memory	219
VI. Unlearned Behaviors	220
E. Summary	221
References	221

CHAPTER 6

Phencyclidine: A Drug of Abuse and a Tool for Neuroscience Research	233
R.L. BALSTER and J. WILLETTTS. With 1 Figure	
A. Introduction and History	233
B. Overview of Pharmacological Profile	234
I. Humans	234
II. Animals	236
C. Cellular Mechanisms of Action	237
I. The Phencyclidine Receptor	237
II. Phencyclidine and the <i>Sigma</i> Binding Site	238
III. Phencyclidine and the NMDA Receptor Complex	239
IV. Behavioral Correlates of Phencyclidine/NMDA Interactions	241
V. Phencyclidine and Dopaminergic Effects – Direct or Indirect Interactions?	243
D. Behavioral Pharmacology of Phencyclidine Abuse	244
I. Discriminative Stimulus Effects	244
II. Self-Administration	245
III. Tolerance and Dependence	246
IV. Modification of Drug Tolerance and Dependence	247
V. Learning and Memory	247
E. Concluding Remarks	248
References	249

CHAPTER 7

Benzodiazepine Discontinuation Syndromes: Clinical and Experimental Aspects	
L.G. MILLER and D.J. GREENBLATT	263
A. Clinical Aspects of Benzodiazepine Discontinuation	263
I. Risk Factors for Benzodiazepine Discontinuation Effects	263
1. Benzodiazepine Compounds	263

2. Dose	264
3. Duration	264
4. Personality Type	264
II. Clinical Benzodiazepine Discontinuation Effects	264
B. Laboratory Aspects of Benzodiazepine Discontinuation	265
I. Behavioral Pharmacology	265
II. Neurochemical Effects	266
C. Conclusion	267
References	267

CHAPTER 8

Nicotine

J.E. HENNINGFIELD, R.M. KEENAN, and P.B.S. CLARKE	271
A. Introduction	271
B. Abuse and Dependence in Humans	271
I. Epidemiology	271
II. Clinical Aspects and Pathophysiology of Nicotine Dependence	273
III. Tolerance and Physical Dependence	274
C. General Pharmacology	276
I. Chemistry and Pharmacokinetics	276
1. Absorption	276
2. Distribution	278
3. Systemic Metabolism	278
4. Brain Metabolic Activity	279
5. Drug Interactions	280
II. Pharmacodynamics	281
1. Cardiovascular Effects	281
2. Electroencephalograph Effects	282
III. Systemic Effects	283
1. Immunologic Effects	283
2. Hormonal Effects	284
3. Toxicity	284
IV. Abuse Liability and Dependence Potential	285
1. Discriminative Effects	285
2. Reinforcing Effects	286
3. Physical Dependence	287
D. Neuropharmacology	288
I. Nicotinic Receptors	288
1. Receptor Diversity	288
2. Receptor Regulation	289
II. Cellular Mechanisms	289
1. Effects of Nicotine on Cell Firing	290

2. Effects of Nicotine on Nerve Terminals	290
3. Effects of Nicotine on Transmitter Release in the Whole Animal	291
III. Neuronal Activity and Mechanisms of Reinforcement	291
1. Mesolimbic Dopamine	292
2. Dorsal Noradrenergic Bundle	294
3. Thalamocortical Projections	295
4. Habenulo-Interpeduncular System	295
5. 5-HT Release	295
6. Amino Acid Neurotransmitter Release	296
7. Acetylcholine Release	296
8. Other Measures of Neuronal Activity	297
9. Peripheral Effects	298
E. Implications for Medications Development and Conclusions	299
References	300

CHAPTER 9

Caffeine Reinforcement, Discrimination, Tolerance and Physical Dependence in Laboratory Animals and Humans

R.R. GRIFFITHS and G.K. MUMFORD. With 2 Figures	315
A. Introduction	315
B. Reinforcing Effects of Caffeine in Laboratory Animals	316
C. Reinforcing Effects of Caffeine in Humans	317
D. Discriminative Stimulus Effects of Caffeine in Laboratory Animals	318
I. Pharmacologic Mechanisms in Drug Discrimination	320
E. Subjective and Discriminative Stimulus Effects of Caffeine in Humans	322
I. Qualitative Subjective Effects of Caffeine	322
II. Demonstration of Caffeine Discrimination	324
III. Acquisition of Caffeine Discrimination	324
IV. Thresholds for Caffeine Discrimination	325
V. Cross-Generalization with Other Drugs	325
VI. Relationship Between Caffeine Discriminative and Subjective Effects	325
VII. Relationship Between Discrimination and Physical Dependence	327
VIII. Relationship Between Discrimination and Reinforcement	327
F. Tolerance to Caffeine in Laboratory Animals	327
I. Role of Adenosine in Tolerance	329
G. Tolerance to Caffeine in Humans	329

H. Caffeine Physical Dependence in Laboratory Animals	330
I. Role of Adenosine in Physical Dependence	332
I. Caffeine Physical Dependence in Humans	333
J. Conclusions	334
References	335

CHAPTER 10

Classical Hallucinogens

R.A. GLENNON. With 7 Figures	343
A. Introduction	343
B. Definitions	345
C. Human vs Nonhuman Investigations	346
D. Models and Assay Methods for Hallucinogenic Activity	347
I. Animal Models	347
II. Nonanimal Models	348
III. The Drug Discrimination Paradigm	349
E. Structure-Activity Relationships	350
I. Indolylalkylamines	351
II. Phenylalkylamines	352
F. Mechanism of Action of Classical Hallucinogens	352
I. The 5-HT Hypothesis	352
II. The 5-HT ₂ Hypothesis	353
III. The 5-HT _{1C} Hypothesis	355
IV. 5-HT _{2A} vs 5-HT _{2C} Receptors	356
1. Studies with Selective Antagonists	356
2. Studies with Lisuride	357
3. Studies with TFMPP	358
4. Radioligand Binding Studies	358
V. Involvement of Other 5-HT Receptors	360
VI. Involvement of Dopamine Receptors	362
G. Structurally Related Agents and Designer Drugs	363
H. Molecular Modeling of Hallucinogen-Receptor Interactions	365
I. Summary	368
References	369

CHAPTER 11

Alcohol

B. TABAKOFF, K. HELLEVUO, and P.L. HOFFMAN. With 1 Figure	373
A. Introduction	373
B. The Metabolism of Ethanol	374
I. Ethanol-Induced Metabolic Anomalies	376

II. Alcohol Dehydrogenase and Microsomal Ethanol Oxidizing Systems.....	379
III. Aldehyde Dehydrogenase	381
IV. Acetate Metabolism and the Metabolic Effects of Acetate	382
C. Actions of Ethanol on the CNS	383
I. Membrane Hypothesis of Ethanol's Actions	383
II. Voltage-Sensitive Calcium Channels	387
III. Neurotransmitter Release	391
1. Dopamine	391
2. Serotonin, Norepinephrine and Acetylcholine	394
IV. Neuropeptides	396
1. Opiates	396
2. Arginine Vasopressin	400
3. Neurotensin	401
V. Postsynaptic Receptors	402
1. Receptor-Effector Coupling Systems	403
VI. Ligand-Gated Ion Channels	415
1. GABA _A Receptors	415
2. Glutamate Receptors	421
3. 5-HT ₃ Receptors	430
D. Conclusion	431
References.....	433

III. Advances in the Pharmacotherapy of Addiction

CHAPTER 12

Pharmacotherapy of Addiction: Introduction and Principles

F.R. LEVIN and H.D. KLEBER.....	461
A. Introduction	461
B. Pharmacologic Interventions	462
I. Agonists	463
1. General Principles and Clinical Indications.....	463
2. Drug Classes	463
II. Antagonists	465
1. General Principles and Clinical Indications.....	465
2. Drug Classes	466
III. Anti-withdrawal Agents	467
1. General Principles and Clinical Indications.....	467
2. Drug Classes	468
IV. Anti-craving Agents	469
C. Conclusion	470
References.....	470

CHAPTER 13

Development of Medications for Addictive Disorders

F.I. Vocci. With 3 Figures	473
A. History of the Regulatory System for New Drugs	473
B. Scheme of New Drug Development	473
C. Phases of Clinical Investigations	476
D. Special Considerations Related to Medications Development for Addictive Disorders	479
E. <i>l</i> - α -Acetylmethadol: Selected Clinical Studies	479
F. Other Necessary Regulatory Actions Regarding <i>l</i> - α -Acetylmethadol	483
G. Summary	483
References	484

CHAPTER 14a

Long-Term Pharmacotherapy for Opiate (Primarily Heroin)**Addiction: Opioid Agonists**

M.J. Kreek	487
A. Introduction	487
B. <i>dl</i> -Methadone (and <i>l</i> -Methadone) as Used in Long-Term Pharmacotherapy of Opiate Addiction	493
I. Chemistry, Pharmacokinetics, Pharmacodynamics, and Mechanisms of Action	493
1. Methadone Disposition in Setting of Chronic Diseases	501
2. Methadone Disposition in Pregnancy	502
3. Drug and Alcohol Interactions with Methadone	503
II. Use of Methadone in Long-Term Pharmacotherapy of Opiate Addiction: "Methadone Maintenance"	506
1. Safety, Efficacy, and Effectiveness	506
III. Neuroendocrine Immune and Gastroenterological Effects of Methadone (As Contrasted with Heroin Addiction)	523
1. Neuroendocrine Function	523
2. Immune Function	528
3. Gastrointestinal Function	530
IV. Special Issues Related to Methadone Maintenance and All Other Long-Term Treatments of Opiate (Heroin) Addicts	531
1. Codependency: Alcoholism, Cocaine, and Other Addictions	531
2. Psychiatric Comorbidity	532

3. Chronic Liver Disease, HIV Infection, and AIDS:
Preexisting Medical Problems in Heroin Addicts
and Impact of Methadone Treatment 533

C. *l*-*a*-Acetylmethadol (LAAM)..... 534

 I. Chemistry, Pharmacokinetics, Pharmacodynamics,
 and Mechanisms of Action in Humans 534

 II. Use of LAAM in Long-Term Pharmacotherapy
 of Opiate Addiction: Safety, Efficacy, and Effectiveness ... 536

 III. Neuroendocrine Effects of LAAM 540

References..... 541

CHAPTER 14b

**Long-Term Pharmacotherapy for Opiate (Primarily Heroin)
Addiction: Opioid Antagonists and Partial Agonists**

M.J. KREEK 563

A. Naloxone, Naltrexone, and Nalmefene
(Mixed Agonists and Antagonists) 563

 I. Chemistry, Pharmacokinetics, Pharmacodynamics,
 and Mechanisms of Action in Humans 563

 II. Use of Naltrexone and Other Opioid Antagonists:
 Safety, Efficacy, and Effectiveness 567

 III. Neuroendocrine Effects of Opioid Antagonists 574

B. Buprenorphine 575

 I. Chemistry, Pharmacokinetics, Pharmacodynamics,
 and Mechanisms of Action in Humans 575

 II. Use of Buprenorphine: Safety, Efficacy,
 and Effectiveness 578

 III. Neuroendocrine Effects of Partial Agonists
 (Mixed Agonists/Antagonists) 590

References..... 592

CHAPTER 15

Pharmacotherapy of Nicotine Dependence

J.R. HUGHES 599

A. Introduction 599

 I. A Brief History of Treatment for Smoking Cessation..... 599

 II. Why Pharmacotherapy? 599

 III. Methodological Issues 600

 1. Paradigms to Test Efficacy 600

 2. Traditions of Testing Medications for Smoking
 vs for Other Drug Dependencies 601

IV. Comparing Medications	601
B. Medications to Aid Smoking Cessation	602
I. Nicotine Replacement	602
1. Nicotine Polacrilex (Nicotine Gum)	602
2. Transdermal Nicotine Systems (Nicotine Patches)	605
3. Patient Selection for Nicotine Replacement	608
4. Other Nicotine Replacement Medications	608
5. Lobeline	608
6. Future Studies on Nicotine Replacement	609
II. Blocking Agents	610
1. Mecamylamine	610
2. Naltrexone	611
III. Clonidine	611
IV. Agents That Make Smoking Aversive	612
1. Silver Acetate	612
2. Other Aversive Agents	612
V. Medications to Abate Withdrawal or Replace the Reinforcing Effects of Nicotine	613
1. Anxiolytics	613
2. Antidepressants	613
3. Stimulants	614
4. Anorectics	615
5. Other Medications	615
C. Use of Adjunctive Psychological Therapies	616
I. Psychological Therapies for Smoking Cessation	616
II. Combining Psychological Therapies and Medications	616
D. Treating Smoking Among Alcohol/Drug Abusers	617
E. Conclusions: Typical Quit Rates	617
References	618

CHAPTER 16

Pharmacotherapies for Cocaine Dependence

E.A. WALLACE and T.R. KOSTEN	627
A. Introduction	627
B. Pharmacologic Treatment of Cocaine Dependence	627
I. Introduction	627
II. Medications Employed in the Treatment of Cocaine Dependence	628
1. Acute Withdrawal Agents	628
2. Chronic Treatment Agents	632
3. Comorbid Psychiatric Disorders	635

Contents	XXV
III. Clinical Considerations	636
1. Indications for Treatment	636
2. Length of Treatment	637
3. Precautions in Treatment	638
References	639
Subject Index	645